Atrium Therapeutics, Inc. (RNA)

Atrium Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Accounts Receivable	-	-	0.75
Other Receivables	0.1	-	-
Receivables	0.1	-	0.75
Prepaid Expenses	1.54	0.48	0.11
Other Current Assets	1.21	-	-
Total Current Assets	2.85	0.48	0.86
Property, Plant & Equipment	5.51	6.7	9.44
Total Assets	8.35	7.19	10.29
Accounts Payable	4.4	0.53	0.5
Accrued Expenses	8.69	1.44	1.5
Current Portion of Leases	3.67	3.84	3.64
Current Unearned Revenue	21.64	20.99	28.16
Other Current Liabilities	3.4	-	-
Total Current Liabilities	41.8	26.8	33.8
Long-Term Leases	-	2.96	6.21
Long-Term Unearned Revenue	28.69	37.96	40.9
Other Long-Term Liabilities	0.57	0.57	-
Total Liabilities	71.07	68.29	80.91
Common Stock	-62.71	-61.11	-70.62
Shareholders' Equity	-62.71	-61.11	-70.62
Total Liabilities & Equity	8.35	7.19	10.29
Total Debt	3.67	6.8	9.85
Net Cash (Debt)	-3.67	-6.8	-9.85
Net Cash Per Share	-0.24	-	-
Filing Date Shares Outstanding	15.51	-	-
Total Common Shares Outstanding	15.51	-	-
Working Capital	-38.96	-26.32	-32.95
Book Value Per Share	-4.04	-	-
Tangible Book Value	-62.71	-61.11	-70.62
Tangible Book Value Per Share	-4.04	-	-
Machinery	5.57	2.03	1.76
Leasehold Improvements	-	0.29	0.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.